基线肌肉减少症和化疗期间骨骼肌丢失对转移性胃癌生存结局的影响
Baseline Sarcopenia and Skeletal Muscle Loss During Chemotherapy Affect Survival Outcomes in Metastatic Gastric Cancer.
作者信息
Sugiyama Keiji, Narita Yukiya, Mitani Seiichiro, Honda Kazunori, Masuishi Toshiki, Taniguchi Hiroya, Kadowaki Shigenori, Ura Takashi, Ando Masashi, Tajika Masahiro, Muro Kei
机构信息
Department of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya, Japan.
Department of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya, Japan
出版信息
Anticancer Res. 2018 Oct;38(10):5859-5866. doi: 10.21873/anticanres.12928.
AIM
To determine the association between sarcopenia and prognosis in patients with metastatic gastric cancer (mGC) receiving chemotherapy.
PATIENTS AND METHODS
Our study retrospectively evaluated 231 consecutive Japanese patients with mGC who commenced first-line chemotherapy at our Institution between January 2013 and December 2015. Muscle loss during chemotherapy was defined as a ≥10% reduction in the skeletal muscle index and was evaluated for its association with time to treatment failure (TTF) and overall survival (OS).
RESULTS
Of 118 patients, 89% had baseline sarcopenia and 31% developed muscle loss. Muscle loss was significantly associated with shorter TTF and OS and was an independent prognostic factor for both these parameters; poor performance status and poorer differentiation on histology were also significant predictors of shorter OS. However, muscle loss was not significantly associated with increased grade 3 or higher toxicities.
CONCLUSION
Muscle loss during chemotherapy negatively affected survival among patients with mGC.
目的
确定接受化疗的转移性胃癌（mGC）患者中肌肉减少症与预后之间的关联。
患者与方法
我们的研究回顾性评估了2013年1月至2015年12月期间在我院开始一线化疗的231例连续的日本mGC患者。化疗期间的肌肉损失定义为骨骼肌指数降低≥10%，并评估其与治疗失败时间（TTF）和总生存期（OS）的关联。
结果
在118例患者中，89%有基线肌肉减少症，31%出现肌肉损失。肌肉损失与较短的TTF和OS显著相关，并且是这两个参数的独立预后因素；体能状态差和组织学上分化较差也是较短OS的显著预测因素。然而，肌肉损失与3级或更高毒性增加无显著关联。
结论
化疗期间的肌肉损失对mGC患者的生存有负面影响。
Zotero 插件